The Fast MDx Platform

Fully automated ultra-safe testing, with inactivate samples, aspirated from sealed Pathtubes® inside the Fast MDx platform.

The first fully automated, high-throughput, Molecular Diagnostic (MDx) test platform to be designed by Festo in Germany.

Fully optimized to work with Fast MDx’s NGx2 qPCR thermal cycler.

With advanced cyber security, the Fast MDx platform seamlessly integrates into all major Laboratory Information Management Systems (LIMS).

We are currently installing an ISO13485 Quality Management System.

The Fast MDx platform has been designed to be manufactured initially with UKCA and CE-IVDr regulatory approvals and subsequently with FDA regulatory approval.


Fast MDx will launch in early 2023, with a CE-IVDr approved, high-throughput, syndromic, respiratory test for flu A, flu B, RSV A, RSV B and COVID-19.

All tests will be MHRA and CE-IVDr approved when launched.